SHE

Across TCGA pan-cancer cohorts, SHE mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SHE data layer compared with 21 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SHE mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SHE expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

LUAD, UCEC, and HNSC are the cancer types where SHE mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.933	0.746	.003	21	view →
UCEC	OS	Quartile	II,III,IV	0.344	1.000	.015	16	view →
HNSC	DFS	Tertile	IV	0.965	0.542	.013	7	view →
CCRCC	DFS	Quartile	All	1.000	0.656	.036	4	view →
LSCC	OS	Median	All	0.921	1.000	.011	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SHE–LUAD (OS)

Open the LUAD breakdown →